Renal and liver injury following the treatment of COVID-19 by remdesivir
Mohsen Mohammad Rahimi, Elham Jahantabi, Behzad Lotfi, Mehdi Forouzesh, Rohollah Valizadeh, Saman Farshid
Abstract
Remdesivir initially was intravenously administrated to treat the Ebola disease however right now it has been administered to treat COVID-19 in some countries. However it is necessary to find the exact effect of remdesivir in patients with COVID-19. Remdesivir solution is administered with a cyclodextrin carrier that filters solely by the glomeruli; thereby patients with abnormal renal function cannot eliminate it quickly; therefore, remdesivir can lead to renal failure or liver dysfunction during therapeutic process of COVID-19. Assessment of renal function in patients with COVID-19 who have acute kidney injury (AKI) or end-stage renal disease is fundamental.